---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-091219"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:16:43.046338+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Corbus Pharma Q2 loss $10M; CRB-701 shows 44% ORR in mUC; cash runway through Q3 2027

## Summary
- Net loss of $10.0M ($0.90 per diluted share) for Q2 2024, compared to net loss of $8.8M ($2.05 per share) in Q2 2023.
- Cash and investments of $147M at June 30; raised $28.8M additional through Aug 1; cash runway extended through Q3 2027.
- CRB-701 Phase 1 data: 44% ORR and 78% DCR in metastatic urothelial cancer; 43% ORR and 86% DCR in cervical cancer at doses ≥1.2mg/kg.
- US/EU Phase 1 dose escalation for CRB-701 commenced April 2024; completion expected Q4 2024; data presentation Q1 2025.
- CRB-913 Phase 1 start expected Q1 2025; CRB-601 Phase 1 start expected Q4 2024; both pre-clinical data support advancement.

## SEC filing metadata
- accession: 0000950170-24-091219
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000095017024091219/0000950170-24-091219-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000095017024091219/crbp-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-091219
- JSON: https://secwatch.observer/filing/0000950170-24-091219.json
- Plain text: https://secwatch.observer/filing/0000950170-24-091219.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.